CenTrial Logo

Sotatercept improves Symptoms for Pulmonary Arterial Hypertension

by


Sototercept found to improve symptoms of pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a rare and severe condition characterized by high blood pressure in the lungs' arteries. PAH occurs when the small arteries in the lungs become narrowed, stiff, or blocked, making it difficult for blood to flow through them. This leads to increased pressure in the pulmonary arteries, which strains the heart and may result in heart failure.

PAH is a chronic and progressive condition that requires careful management by a specialized healthcare team. Symptoms of PAH can include shortness of breath, fatigue, chest pain, dizziness, swelling in the ankles or legs, and fainting. Treatment options for PAH include medications to dilate blood vessels, reduce inflammation, and lower blood pressure in the lungs, as well as lifestyle changes such as exercise, oxygen therapy, and avoiding triggers that worsen symptoms.

Clinical Trial

In a trial, researchers investigated the safety and efficacy of sotatercept, a potential treatment for PAH, in an open-label extension of a phase 2 clinical trial called PULSAR. The trial followed participants who received sotatercept for up to 24 months and evaluated its effects on PAH symptoms and overall health.

The PULSAR study initially enrolled 106 participants with PAH who were randomly assigned to receive either sotatercept or placebo in addition to their standard PAH therapy. After the initial 24-week study period, participants who had received a placebo were re-randomized to receive either sotatercept at different doses (0.3 or 0.7 mg·kg-1) or continue with placebo (placebo-crossed group), while those who had received sotatercept continued with their original dose (continued-sotatercept group). The safety and efficacy of sotatercept were evaluated in all participants who received at least one drug dose during the extension period.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me

Findings

The results showed that sotatercept was generally well-tolerated, with a low incidence of serious adverse events. Only 9.6% of participants reported adverse events that led to the discontinuation of the study, and none of the deaths that occurred during the study were related to the study drug. Notably, both the placebo-crossed and continued-sotatercept groups demonstrated significant improvement in primary and secondary efficacy endpoints, including a reduction in pulmonary vascular resistance and improvements in exercise capacity as measured by the 6-minute walk distance and functional class.

Conclusion

Sotatercept may be a safe and effective long-term treatment option for patients with PAH. The results support the durability of the clinical benefits of sotatercept in improving PAH symptoms and overall health over an extended treatment period. However, it's important to note that further research and more extensive studies are needed to confirm these findings and fully understand the safety and efficacy of sotatercept in the management of PAH. Patients with PAH should consult their healthcare provider for appropriate treatment options and management plans tailored to their needs.
__________



Share this article with a friend:
     


Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Whether you're healthy or have a medical condition you can participate in a clinical trial.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.


This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.